| Scleroderma |
1 |
0.95 |
| Interstitial Lung Disease |
0 |
1 |
| Lung |
0 |
0.65 |
| Biomarker |
0 |
0.8 |
| Lung Fibrosis |
0 |
0.49 |
| Systemic Sclerosis |
0 |
0.95 |
| Bronchoalveolar Lavage |
0 |
0.8 |
| California |
0 |
0.16 |
| Biologic Therapy |
0 |
0.08 |
| Care and Maintenance of Vision |
0 |
0.08 |
| Cataract |
0 |
0.08 |
| Genomic Medicine |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Idiopathic Pulmonary Fibrosis |
0 |
0.08 |
| Otolaryngology |
0 |
0.08 |
| Prognosis |
0 |
0.08 |
| Stem Cell Research and Therapy |
0 |
0.08 |
| Connective Tissue Disease |
0 |
0.06 |
| A-Scan Biometry |
0 |
0.04 |
| Brachial |
0 |
0.04 |
| Bronchoscopy |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Europe |
0 |
0.04 |
| Immunosuppressive Therapy |
0 |
0.04 |
| Interleukin |
0 |
0.04 |
| Muscle |
0 |
0.04 |
| Pharmacogenomics |
0 |
0.04 |
| Scan |
0 |
0.04 |
| Surfactant |
0 |
0.04 |
| Thorax |
0 |
0.04 |
| Tissue |
0 |
0.04 |
| Weakness |
0 |
0.04 |